Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.56 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.54 |
| ▸ | BAD | Q92934 | 1/20 | 0.54 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 2/20 | 0.48 |
| ▸ | RXRB | P28702 | 2/20 | 0.48 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15939679 | 0.98 | MAP4K4 (0.59) | MAP4K4CA1CA2MMP3BCL2L1 | |
| SCHEMBL216706 | 0.93 | CA2 (0.64) | MAP4K4CA1CA2SLC22A12AR | |
| SCHEMBL28435413 | 0.91 | CA2 (0.61) | MAP4K4CA1CA2SLC22A12AR | |
| SCHEMBL15347438 | 0.91 | CA2 (0.61) | MAP4K4CA1CA2SLC22A12AR | |
| Hydrochloric Acid SCHEMBL3184981 | 0.91 | CA2 (0.61) | MAP4K4CA1CA2SLC22A12AR | |
| SCHEMBL27765473 | 0.91 | CA2 (0.61) | MAP4K4CA1CA2SLC22A12AR | |
| Ammonia Solution, Strong SCHEMBL22265084 | 0.91 | CA2 (0.61) | MAP4K4CA1CA2SLC22A12AR | |
| SCHEMBL11453092 | 0.91 | CA2 (0.61) | MAP4K4CA1CA2SLC22A12AR | |
| Benzoic Acid SCHEMBL9405473 | 0.90 | TSHR (0.54) | MAP4K4CA1CA2MMP3SLC22A12 | |
| SCHEMBL23037552 | 0.89 | CA2 (0.59) | MAP4K4CA1CA2BCL2L1BAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10118919-B2 | 3-substituted cyclopentylamine derivatives | MERCK PATENT GMBH (DE) | 2018-11-06 | — | — | US | claimed |
| EP-3033339-B1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-02-28 | — | — | EP | claimed |
| US-20180022738-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | claimed |
| US-9732032-B2 | 3-aminocyclopentane carboxamide derivatives | MERCK PATENT GMBH (DE) | 2017-08-15 | — | — | US | claimed |
| CN-104797553-B | 3 aminocyclopentanecarasxamides derivatives | 默克专利股份公司 | 2017-07-21 | — | — | CN | claimed |
| EP-2920146-B1 | 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-28 | — | — | EP | claimed |
| US-20160264517-A1 | 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | claimed |
| US-20160200714-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-14 | — | — | US | claimed |
| EP-3033339-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | Merck Patent GmbH (DE) | 2016-06-22 | — | — | EP | claimed |
| EP-2920146-A1 | 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2015-09-23 | — | — | EP | claimed |
| US-20060122432-A1 | Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol | GLAXO GROUP LIMITED (GB) | 2006-06-08 | — | — | US | claimed |
| EP-1534280-A1 | ARYL PIPERIDINE DERIVATIVES AND USE THEREOF TO REDUCE ELEVATED LEVELS OF LDL-CHOLESTEROL | GLAXO GROUP LIMITED (GB) | 2005-06-01 | — | — | EP | claimed |
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | BOUILLOT ANNE (FR) | 2004-07-29 | — | — | US | claimed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | claimed |
| WO-2004006923-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| WO-2004006924-A1 | ARYL PIPERIDINE DERIVATIVES AND USE THEREOF TO REDUCE ELEVATED LEVELS OF LDL-CHOLESTEROL | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | claimed |
| EP-1351937-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | claimed |
| WO-2002055497-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | claimed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264517-A1 | 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | FADS1, FASN, FFAR3 | MAP4K4 2216/4885CA1 1598/4885CA2 1430/4885 |
| US-20180022738-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | FASN, FADS1, ACOX3 | MAP4K4 2959/4885CA1 3025/4885CA2 3251/4885 |
| US-10118919-B2 | 3-substituted cyclopentylamine derivatives | FASN, FADS1, ACOX3 | MAP4K4 2959/4885CA1 3025/4885CA2 3251/4885 |
| US-20160200714-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | FASN, FADS1, ACOX3 | MAP4K4 2959/4885CA1 3025/4885CA2 3251/4885 |
| US-20060122432-A1 | Aryl piperidine derivatives and use thereof to reduce elevated levels of ldl-cholesterol | LDLR, NR1H2, NR1H3 | MAP4K4 3202/4885CA1 4884/4885CA2 4866/4885 |
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | MAP4K4 3837/4885CA1 4369/4885CA2 3024/4885 |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | MAP4K4 2688/4885CA1 4856/4885CA2 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.